Laurie Hudson, PhD
Professor & UNM Regents' Professor: Pharmaceutical Sciences
Office Location: RIB225
Phone: (505) 272-2482
Hudson received a BS in zoology and a BS in biology from the University of Washington in 1980 and her PhD in pharmacology and toxicology from Harvard University in 1985. She completed post-doctoral training in molecular endocrinology at the University of California, San Diego, and joined the UNM faculty in 1997.
Hudson has two major areas of research – mechanisms by which environmental metals disrupt protein function with an emphasis on inhibition of DNA repair, and investigating novel therapeutics for ovarian cancer and understanding molecular drivers of cancer metastasis. Her expertise is in skin and ovarian cancers and cellular mechanisms that lead to cancer development and progression. Hudson’s laboratory conducts investigations through biochemical, cell biological, in vivo and human translational approaches. She investigates novel therapeutics for ovarian cancer, which has led to a pilot clinical trial to investigate the pharmacokinetics and pharmacodynamics of a candidate therapeutic drug. Investigations on the mechanisms of environmental metal toxicity are moving into exposed human populations in the Southwest.
- American Association for Cancer Research
- American Society for Biochemistry and Molecular Biology
- American Association for the Advancement of Science
UNM Cancer Center Scientists Discover that an Anti-Inflammatory Drug Acts Against Ovarian Cancer
(Cancer Center News July 28, 2015) ─ A team of scientists at the University of New Mexico Cancer Center published a research paper showing that a non-steroidal anti-inflammatory drug (NSAID) called ketorolac helped women with ovarian cancer to survive longer.